Compare D R Horton Inc (DHI) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Incyte Corporation — how do they compare? D R Horton Inc trades at $134.88 (market cap $37.99B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: D R Horton Inc is the larger of the two by market cap, and D R Horton Inc pays a 1.33% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold D R Horton Inc for 46 Days and Incyte Corporation for 33 Days on average.
| DHI | INCY | |
|---|---|---|
Market Cap | $37.99B | $22.85B |
Volume | 2,974,460 | 1,927,029 |
Sector | Consumer Cyclical | Health |
52-Week High | $167.78 | $129.93 |
52-Week Low | $132.53 | $83.80 |
Typical Hold Time | 46 Days | 33 Days |
Enterprise Value | $43.09B | $18.35B |
Dividend Yield | 1.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DHI trades at $134.88, up 1.2% on the day, with a bearish technical signal and neutral oscillators. The stock has beaten earnings estimates in recent quarters, with a P/E of 12.95 and net income margin of 9.15%. Recent news highlights pressure from rising mortgage rates, with the 30-year fixed rate potentially spiking to 9% according to Selma Hepp on CNBC (2026-09-28), impacting homebuilder sentiment.
The outlook is mixed: strong fundamentals and analyst consensus price target of $156.57 offer upside, but macroeconomic risks from interest rates and housing market weakness pose headwinds. Earnings growth remains a key catalyst, yet affordability concerns could dampen near-term performance.
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
